Abstract | OBJECTIVES: To investigate immune-mediated necrotizing myopathy (IMNM) association with cancer and its clinical implications. METHODS: IMNM cases were identified 1 January 2000 to 31 December 2020 matching sex and age controls (4:1). RESULTS: A total of 152 patients with IMNM were identified and among serologically tested, 60% (83/140) were HMGCR- IgG+, 14% (20/140) were SRP-IgG+ and 26% (37/140) were seronegative. Cancer rates were not significantly different between serological subgroups; 18.1% (15/83) HMGCR- IgG+, 25% (5/20) SRP-IgG+ and 30% (11/37) seronegative (P = 0.34). Cancer screening was performed within 12 months from IMNM diagnosis in 88% (134/152) (whole-body CT plus FDG-PET CT in 53, CT alone in 72 and FDG-PET alone in 9). FDG-PET/CT was positive in 73% (25/34) of cancers. Increasing age was the only risk associated with cancer (P = 0.02). The odds of developing cancer at ±3 or ±5 years from IMNM diagnosis was not higher than controls (OR = 0.49; CI: 0.325-0.76). Lifetime IMNM diagnosis of cancer was less compared with controls (OR = 0.5 CI: 0.33-0.78, P = 0.002). Most patients responded to treatment (137/147, P < 0.001). Death and treatment response did not significantly differ between cancer [23% (8/34); 88% (29/33)] and non- cancer patients [19% (23/118); 92% (108/118)]. In total, 13% (20/152) of patients died during follow-up compared with 14% (41/290) of medicine and 16% (46/290) of neurology controls (P = 0.8). Seropositives had greater life expectancy than seronegatives (P = 0.01). CONCLUSIONS: Greater cancer risk is not observed in IMNM vs controls. Cancer screening in IMNM should be individualized based on age-personal and family history, including consideration of FDG-PET/CT. Immune-treatment response did not differ with cancer.
|
Authors | Shahar Shelly, Grayson Beecher, Margherita Milone, Teerin Liewluck, Floranne Ernste, James Triplett, Elie Naddaf, Anastasia Zekeridou, Andrew McKeon, Sean J Pittock, Divyanshu Dubey, John R Mills, Jay Mandrekar, Christopher J Klein |
Journal | Rheumatology (Oxford, England)
(Rheumatology (Oxford))
Vol. 62
Issue 1
Pg. 281-289
(12 23 2022)
ISSN: 1462-0332 [Electronic] England |
PMID | 35285492
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: [email protected]. |
Chemical References |
- Fluorodeoxyglucose F18
- Immunoglobulin G
- Autoantibodies
|
Topics |
- Humans
- Muscle, Skeletal
- Fluorodeoxyglucose F18
- Positron Emission Tomography Computed Tomography
- Necrosis
- Myositis
(diagnostic imaging, epidemiology)
- Autoimmune Diseases
(complications, diagnostic imaging, epidemiology)
- Neoplasms
(diagnostic imaging, epidemiology, complications)
- Immunoglobulin G
- Autoantibodies
- Muscular Diseases
(diagnostic imaging, epidemiology, complications)
|